Results 51 to 60 of about 66 (62)

OROS methylphenidate for the treatment of adults with attention-deficit/hyperactivity disorder

Expert Review of Neurotherapeutics, 2009
J Antoni Ramos-Quiroga, Xavier Castells, Rosa Bosch   +2 more
exaly  

Outcomes of OROS® methylphenidate compared with atomoxetine in children with ADHD: A multicenter, randomized prospective study

Advances in Therapy, 2005
exaly  

Efficacy and tolerability of once-daily OROS® hydromorphone and twice-daily extended-release oxycodone in patients with chronic, moderate to severe osteoarthritis pain: Results of a 6-week, randomized, open-label, noninferiority analysis

Clinical Therapeutics, 2007
exaly  

Gastric emptying of OROS tablets in man

International Journal of Pharmaceutics, 1984
exaly  

The clinical profile of children with ADHD that require OROS-methylphenidate combined with shorter-acting formulations

ADHD Attention Deficit and Hyperactivity Disorders, 2015
exaly  

Quantitative determination of polymorphic impurity by X-ray powder diffractometry in an OROS® formulation

International Journal of Pharmaceutics, 2009
exaly  

Mikronährstoffsupplemente bei onkologischen Patienten

Aktuelle Ernahrungsmedizin Klinik Und Praxis, 2011
exaly  

Arzneimittel und Mikronährstoffe

Ernährung & Medizin, 2013
exaly  

Use of OROS® hydromorphone in the treatment of osteoarthritis and osteoporosis: A pooled analysis of three non-interventional studies focusing on different starting doses

Wiener Klinische Wochenschrift, 2011
exaly  

Comparative bioavailability and steady state fluctuations of tegretol commercial and carbamazepine oros tablets in adult and pediatric epileptic patients

Biopharmaceutics and Drug Disposition, 1992
exaly